The Russian Direct Investment Fund (RDIF) commented on the results presented by AstraZeneca on the effectiveness of the British vaccine against COVID-19.
RDIF drew attention to the use of a chimpanzee adenoviral vector in a foreign preparation.
“A possible reason for the 62% effectiveness of the full dose of AstraZeneca is that the immunity to the chimpanzee adenovirus vector after the 1st injection makes the 2nd injection (the same vector
- RT
) ineffective.
Sputnik V solves this problem by using two different human adenoviral vectors for two injections (92% efficiency), ”says the official Twitter account of the Russian Sputnik V vaccine.
The possible reason for 62% efficacy of AstraZeneca's full dose regiment is that immunity to chimpanzee adenoviral vector from the 1st shot makes 2nd shot not effective.
#SputnikV addresses this issue by using two different human adenoviral vectors for two shots (92% efficacy)
- Sputnik V (@sputnikvaccine) November 23, 2020
Earlier it became known that an interim analysis of clinical trials of the British vaccine AstraZeneca against coronavirus infection COVID-19 showed its average efficiency at the level of 70%.
In a press release, the company clarifies that this figure is based on data on the effectiveness of two dosing regimens.
In the first case, the vaccine was administered as a half dose, followed by a full dose at an interval of at least one month, and in the second, two full doses were administered at an interval of at least one month.
The first mode showed efficiency at the level of 90%, and the second - at the level of 62%.
British Prime Minister Boris Johnson welcomed the data on the effectiveness of the AstraZeneca vaccine, which is being developed in collaboration with experts from Oxford.
“It's incredibly impressive news that the Oxford vaccine has been so effective in trials.
There are further security checks ahead, but these are fantastic results, ”the head of the British government wrote on Twitter.
United Kingdom Health Minister Matt Hancock called the data on the effectiveness of the AstraZeneca vaccine "encouraging".
“This is really encouraging news about the Oxford and AstraZeneca vaccine, which we obviously support from the beginning.
And I am actually very happy, really welcome these numbers, these data, which show that a vaccine with the correct dosage can be up to 90% effective, ”SkyNews quotes Hancock.
According to him, there is an order for 100 million doses of the vaccine, most of which should be completed this year.
In addition, in the summer of 2020, the European Commission entered into an agreement with British pharmacists for the supply of 300 million doses of the drug (with the possibility of acquiring another 100 million), as well as Argentina for the purchase of 22 million doses.
The report on the effectiveness of the drug AstraZeneca was also evaluated by the former head of the department of microbiology of latent infections of the National Research Center for Epidemiology and Microbiology named after honorary academician N.F.
Gamalei professor Victor Zuev.
In an interview with RT, the expert also recalled that the effectiveness of the Russian Sputnik V vaccine is 92%.
“Can you compare 70% and 92%?
It is possible, of course, but, obviously, in favor of 92%.
An excellent vaccine that we have created, it has already shown itself excellently, ”Zuev said.
He added that he himself had been vaccinated.
“I am 92 years old and have an antibody titer of 1 in 3200. After that, what can we say about the London vaccine?
I don’t know if we need to talk about it at all, ”the speaker concluded.
Reuters
© Tatyana Makeyeva
We will remind, in Russia in August the vaccine "Sputnik V" was registered by the Center.
Gamalei.
In November it became known that the effectiveness of the drug according to the results of the first interim analysis of the third phase of clinical trials in Russia was 92%.
According to the vaccine developers, the studies evaluated the effectiveness of more than 16,000 volunteers 21 days after receiving the first dose of the vaccine or placebo.
The statistical analysis included 20 confirmed cases.
In addition, observation of 10 thousand vaccinated among additional volunteers outside of clinical trials confirmed the effectiveness of Sputnik V at over 90%.
In November, the Ministry of Health of the Russian Federation said that the third phase of trials of the Russian vaccine against coronavirus "Sputnik V" shows that its effectiveness is "extremely high."
Note that in October, the second vaccine was registered in Russia - "EpiVacCorona" by the "Vector" center.
It is expected that the drug will enter civilian circulation by the end of the year.
Another drug is at the stage of clinical trials, which is being developed by the Center for Research and Development of Immunobiological Drugs named after M.P.
Chumakov RAS.
As the head of the Ministry of Health Mikhail Murashko said in November, clinical trials of the third vaccine should be completed in December.
Russian Prime Minister Mikhail Mishustin said that all COVID-19 vaccines will be included in the list of vital and essential medicines.
“They should be available to everyone who wants to get such a vaccine,” the head of government said at a meeting of the presidium of the coordination council under the Russian government to combat the spread of coronavirus.